Qu Biologics Initiates Study of Site Specific Immunomodulators at Geisel School of Medicine at Dartmouth

VANCOUVER, BRITISH COLUMBIA--(Marketwired - July 3, 2013) - Qu Biologics Inc., a biopharmaceutical company developing Site Specific Immunomodulators (SSIs) that aim to "reboot" the body's immune system, announced it has initiated preclinical research to further demonstrate the mechanism by which SSI therapy leads to the killing of cancer cells. The study will be conducted at the laboratory of Dr. David Mullins at the Norris Cotton Cancer Center and the Geisel School of Medicine at Dartmouth in Lebanon, New Hampshire.

"We are very pleased to be working with the Geisel School of Medicine at Dartmouth and Dr. David Mullins, a leader in the field of cancer immunology, on this important collaborative research," said Dr. Hal Gunn, CEO of Qu Biologics. "This research has the potential to deepen our understanding of SSI therapy and provide the foundation for a second generation of immunotherapies based on the SSI platform technology," Dr. Gunn added.

Dr. Mullins commented, "We're very excited to be working with Qu Biologics and their innovative SSI technology. Evaluating SSI function and efficacy in our model systems will enhance our understanding of immune-mediated regulation of cancer, and these studies may pave the way for novel combinatorial therapies that will enhance SSI function."

Dr. Mullins' lab studies immune cell infiltration of tumors and develops novel immunotherapy approaches for the treatment of metastatic cancers. Dr. Mullins' lab will apply their expertise and models to investigate the immunologic mechanisms of SSI-mediated site specificity and anti-tumor activity. These studies will extend Qu Biologics' preclinical capabilities and provide new models in which to evaluate the molecular and cellular mechanisms of SSI anti-cancer therapy.

About Dr. David Mullins

Dr. Mullins is Assistant Professor of Microbiology and Immunology in the Norris Cotton Cancer Center at the Geisel School of Medicine at Dartmouth (Hanover, New Hampshire). He received his PhD in Immunology from Virginia Polytechnic Institute and State University (Virginia Tech), and completed advanced training in tumor immunology at the University of Virginia. Dr. Mullins is a recognized expert in immune cell trafficking to tumors. Through translational research models and clinical trials, he continues to investigate and develop novel strategies for immune therapy of metastatic cancers. Dr. Mullins is an active member of the Society for the Biological Therapy of Cancer, the American Association of Immunologists, and the American Association for Cancer Research. Dr. Mullins serves as a reviewer for leading immunology journals (including the Journal of Immunology, Cancer Research, Clinical Cancer Research, and the Journal of Immunotherapy), and he's a member of the Editorial Boards of the Journal of Immunotherapy Applications and the Journal of Immunology and Clinical Research.

About Qu Biologics

Qu Biologics develops Site Specific Immunomodulators (SSI), a novel class of immunotherapies that aim to reboot the body's immune system. SSIs are designed to stimulate an immune response in targeted organs or tissues to potentially reverse the chronic inflammation underlying many conditions including cancer and autoimmune disease.

Backed by a prestigious group of scientific advisors and board members, Qu Biologics is led by a management team that includes co-founder and CEO Dr. Hal Gunn, a physician and expert on the body's immune response to chronic disease; and Chief Medical Officer Dr. Simon Sutcliffe, former CEO of the BC Cancer Agency and a distinguished clinician, scientist and leader in cancer control in Canada and internationally. For more information, visit www.qubiologics.com and www.qucrohnstrial.com.